Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, today announced the appointment of Dr. Stuart Silverman, M.D., FACP, FACR, as Senior Vice President of Medical Affairs. Dr. Silverman will also continue to serve as Co-Chair of Kalytera’s Scientific Advisory Board.
“I am honored to fill this important position,” said Dr. Silverman. “I will initially support the advancement of our development programs in osteoporosis, bone fracture healing, and osteogenesis imperfecta. Preclinical data supports the continued investigation of Kalytera’s drug candidates in these areas. In addition, recent mainstream media coverage has highlighted patient concerns about starting or continuing existing osteoporosis medications due to perceived side effects. As a clinician, I recognize that there is a significant need for effective new therapies with favorable side effect profiles.”
Dr. Stuart Silverman, M.D., FACP, FACR
Dr. Silverman is a Clinical Professor of Medicine at the University of California, Los Angeles, David Geffen School of Medicine. He is a member of the International Osteoporosis Foundation’s (“IOF”) Committee of Scientific Advisors. In addition, he is the American Society of Bone and Mineral Research representative to the National Osteoporosis Foundation Interspecialty Medical Council.
Dr. Silverman developed the Osteoporosis Assessment Questionnaire, or OPAQ, a measure of quality of life in osteoporosis used globally, and was part of the World Health Organization task force that developed FRAX, an international algorithm to assess ten-year fracture risk. He recently led an IOF consensus report on fracture healing.
“Dr. Silverman is a highly respected and influential authority on osteoporosis and bone health and we’re thrilled to have him as a member of our leadership team,” said Dr. Raphael Mechoulam, Ph.D., Co-Chair of Kalytera’s Scientific Advisory Board. “Stuart’s deep knowledge of bone, and his experience as a medical practitioner, will be of great value to Kalytera as we advance towards human clinical studies.”
About Dr. Stuart Silverman, M.D., FACP, FACR
Dr. Silverman is a Clinical Professor of Medicine at the University of California, Los Angeles, David Geffen School of Medicine and he is a Clinical Professor of Medicine at Cedars-Sinai Medical Center in Los Angeles. He is Board Certified in internal medicine, rheumatology, and allergy-immunology.
Dr. Silverman serves as Medical Director of the OMC Clinical Research Center which runs clinical trials for patients with fibromyalgia, osteoporosis, women’s health, osteoarthritis, and rheumatoid arthritis. The OMC has been the recipient of both federal (“NIH”) and state grants and is a member of the National Bone Health Association.
Dr. Silverman lectures internationally and domestically on his areas of expertise featuring fibromyalgia and osteoporosis. He is the American Society of Bone and Mineral Research (“ASBMR”) representative to the National Osteoporosis Foundation Interspecialty Medical Council, and a member of the Council of Scientific Advisors of the International Osteoporosis Foundation. He is the developer of the Osteoporosis Assessment Questionnaire, or OPAQ, a measure of quality of life in osteoporosis used globally. He was part of the original World Health Organization taskforce that developed FRAX, an international algorithm to assess ten-year fracture risk. He has served on a Joint Commission task force to develop process measures to assess quality of hospital care in osteoporosis.
Dr. Silverman completed his undergraduate education at Princeton University and received his M.D. from Johns Hopkins. He was an intern, resident, and rheumatology fellow at Boston University. Following his rheumatology fellowship, he was a Thorndike research fellow. He has served as a lecturer at Tufts University and as an assistant professor at the University of Pennsylvania. Dr. Silverman is the author of over 200 original articles, 100 abstracts, and ten book chapters.
Kalytera Therapeutics is developing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like medicines intended to address the unmet needs of large patient populations. Kalytera seeks to commercialize its proprietary synthetic cannabinoid therapies across a range of disease states, with an initial focus on bone health.
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Kalytera. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Kalytera cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Kalytera will not obtain appropriate or necessary governmental approvals to market these or other potential products, Kalytera may not be able to obtain anticipated funding for its development projects or other needed funding, and Kalytera may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Kalytera does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.